Subject(s)
Benzophenones , Bromobenzenes , Ophthalmic Solutions , Stevens-Johnson Syndrome , Humans , Stevens-Johnson Syndrome/etiology , Stevens-Johnson Syndrome/diagnosis , Stevens-Johnson Syndrome/pathology , Stevens-Johnson Syndrome/drug therapy , Ophthalmic Solutions/adverse effects , Benzophenones/adverse effects , Benzophenones/administration & dosage , Bromobenzenes/adverse effects , Bromobenzenes/administration & dosage , Female , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , MaleABSTRACT
Increasing evidence has been published over recent years on the implication of endocrine-disrupting chemicals (EDCs), including parabens and benzophenones in the pathogenesis and pathophysiology of endometriosis. However, to the best of our knowledge, no study has been published on the ways in which exposure to EDCs might affect cell-signaling pathways related to endometriosis. We aimed to describe the endometriotic tissue expression profile of a panel of 23 genes related to crucial cell-signaling pathways for the development and progression of endometriosis (cell adhesion, invasion/migration, inflammation, angiogenesis, and cell proliferation/hormone stimulation) and explore its relationship with the exposure of patients to parabens (PBs) and benzophenones (BPs). This cross-sectional study included a subsample of 33 women with endometriosis from the EndEA study, measuring their endometriotic tissue expressions of 23 genes, while urinary concentrations of methyl-, ethyl-, propyl-, butyl-paraben, benzophenone-1, benzophenone-3, and 4-hydroxybenzophenone were determined in 22 women. Spearman's correlations test and linear and logistic regression analyses were performed. The expression of 52.2% of studied genes was observed in >75% of endometriotic tissue samples and the expression of 17.4% (n = 4) of them in 50-75%. Exposure to certain PB and BP congeners was positively associated with the expression of key genes for the development and proliferation of endometriosis. Genes related to the development and progression of endometriosis were expressed in most endometriotic tissue samples studied, suggesting that exposure of women to PBs and BPs may be associated with the altered expression profile of genes related to cellular pathways involved in the development of endometriosis.
Subject(s)
Endocrine Disruptors , Endometriosis , Humans , Female , Parabens/adverse effects , Endometriosis/chemically induced , Endometriosis/genetics , Cross-Sectional Studies , Benzophenones/adverse effectsABSTRACT
Widespread use of benzophenones (BPs), a group of environmental phenolic compounds, is suspected of interfering with human health. The association of prenatal exposure to benzophenone derivatives with birth outcomes including birth weight and length, head, arm and thoracic circumference, abnormalities, corpulence index and anterior fontanelle diameter (AFD) was investigated. Mother-infant pairs of 166 within PERSIAN cohort population in Isfahan, Iran, in the 1st and 3rd trimesters of pregnancy were assessed. Four common benzophenone metabolites including 2,4-dihydroxy benzophenone (BP-1), 2-hydroxy-4-methoxy benzophenone (BP-3), 4-hydroxy benzophenone (4-OH-BP) and 2,2'-dihydroxy-4-methoxy benzophenone (BP-8) were measured in maternal urine samples. The median concentration of 4-OH-BP, BP-3, BP-1 and BP-8 were 3.15, 16.98, 9.95 and 1.04 µg/g Cr, respectively. In the 1st trimester, 4-OH-BP showed a significant correlation with AFD in total infants, decreasing 0.034 cm AFD per a log unit increase of 4-OH-BP. Within the male neonates, 4-OH-BP in the 1st and BP-8 in the 3rd trimester were significantly associated with head circumference and AFD increase, respectively. Among female neonates in the 3rd trimester, increasing 4-OH-BP and BP-3 concentration was correlated with a decrease in birth weight and AFD, respectively. This study demonstrated that all the target BP derivatives can influence normal fetal growth at any age of the pregnancy, nevertheless, to support these findings further studies are needed in a large and different group population.
Subject(s)
Benzophenones , Maternal Exposure , Infant, Newborn , Infant , Humans , Male , Pregnancy , Female , Maternal Exposure/adverse effects , Birth Weight , Benzophenones/adverse effects , MothersABSTRACT
Background: Benzophenone (BZP)-3 and BZP-4 are ultraviolet (UV) absorbers used in sunscreens and personal care products (PCPs) and may cause allergic contact dermatitis. Objective: To characterize positive patch test reactions to BZP-3 (10% in petrolatum [pet]) and BZP-4 (2% pet) in a screening allergen series. Methods: Retrospective analysis of patients tested to BZP-3 and BZP-4 was conducted by the North American Contact Dermatitis Group from 2013 to 2020. Results: Of 19,618 patients patch tested to BZP-3 and BZP-4, 103 (0.5%) and 323 (1.6%) had positive reactions, respectively: 413 (2.1%) reacted to at least 1 BZP (BZP-positive patient). As compared with BZP-negative patients, BZP-positive patients were significantly more likely to have a history of hay fever (39.3% vs 33.4%, P = 0.0134), history of atopic dermatitis (39.8% vs 30.7%, P = 0.0001), and facial involvement (37.4% vs 32.2%, P = 0.0272). Most reactions were currently clinically relevant (BZP-3: 90.4%; BZP-4: 65.8%). Common identified sources included PCPs and sunscreens. Coreactivity between BZP-3 and BZP-4 was low: 13.5% (14/104) of BZP-3-positive patients were allergic to BZP-4 and 4.3% (14/322) of BZP-4-positive patients were allergic to BZP-3. Conclusions: Eight-year prevalence of BZP positivity was 2.1%. Reactions were frequently clinically relevant and linked to PCPs and sunscreens.
Subject(s)
Dermatitis, Allergic Contact , Sunscreening Agents , Humans , Patch Tests/adverse effects , Sunscreening Agents/adverse effects , Retrospective Studies , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/epidemiology , Dermatitis, Allergic Contact/etiology , Allergens , Benzophenones/adverse effects , North America/epidemiologyABSTRACT
Introduction: Environmental exposure during fetal life may disrupt testicular development. In humans, a limited number of studies have investigated whether these adverse effects persist into adulthood. Using data from a prospective, population-based birth cohort study, The Copenhagen Mother-Child cohort, the objective was to assess if there is an association between fetal exposure to selected phenols and benzophenones and markers of testicular function in adult men. Methods: Pregnant women were recruited in 1997-2001. Their sons were examined clinically at 18-20 years of age, with focus on adult markers of reproductive function (anogenital distance (AGD), semen quality and reproductive hormones). In total, 101 18-20-year-old men were included, whose mothers during pregnancy had a serum sample drawn and analyzed for bisphenol A (BPA) and seven other simple phenols, as well as six benzophenones. To investigate the association between chemical levels (in tertiles, T1-T3) in relation to markers of reproductive function, univariate and multiple linear regression analyses were performed. Results: In fully adjusted analyses, increased levels of luteinizing hormone (LH) were observed with higher fetal exposure to BPA (percentage difference (95%CI)) (T2: 12% (-8%,36%) and T3: 33% (10%,62%), compared to T1) and benzophenone-3 (BP-3) (T2: 21% (-2%,49%), T3: 18% (-4%,45%)), while no clear association was seen to total testosterone (TT). Higher levels of BPA and BP-3 were associated with a lower TT/LH ratio, although only significant for BPA (p-trend=0.01). No associations were seen to AGD or markers of semen quality. Conclusion: In conclusion, high exposure to BPA and BP-3 was associated with a compensated reduced Leydig cell function but no other changes in markers of reproductive health. As maternal levels of BPA and BP-3 were not correlated, separate effects may be at play. Larger studies on long-term reproductive consequences of prenatal exposures are warranted to validate our findings.
Subject(s)
Prenatal Exposure Delayed Effects , Semen Analysis , Adult , Humans , Male , Female , Pregnancy , Prenatal Exposure Delayed Effects/chemically induced , Cohort Studies , Prospective Studies , Luteinizing Hormone , Testosterone , Phenols/adverse effects , Benzophenones/adverse effectsABSTRACT
BACKGROUND: Allergic contact dermatitis (ACD) and photoallergic contact dermatitis (PACD) to benzophenone present in printing ink have been reported. However, precise chemical analyses and extended photo-patch tests have not been performed in these cases. OBJECTIVES: To determine which components present in a magazine cover are responsible for a patient's skin reaction, to determine the primary sensitizer, and precisely diagnose ACD and PACD. METHODS: After initial photo-patch tests were performed on a patient with a history of reaction to magazine covers after sun exposure, gas chromatography-mass spectrometry and high-performance liquid chromatography analyses of the magazine covers, and additional photo-patch tests were performed. RESULTS: The first photo-patch test results confirmed PACD to ketoprofen and fenofibrate and evoked PACD to the magazine covers. 4-methyl benzophenone (4-MBP) and 1-hydroxy-cyclohexyl-phenyl-ketone (1-HCPK) were found in the magazine cover. Additional photo-patch tests confirmed PACD to 1-HCPK and to benzophenone, and photo-aggravated ACD to 4-MBP. The primary sensitizer was ketoprofen. CONCLUSIONS: Benzophenones are present in a wide variety of products, without always being listed on the packaging. Patients previously sensitized to other ketones, such as ketoprofen, may react to benzophenones without being able to avoid contact with these molecules. New regulations may be needed for more efficient eviction advice.
Subject(s)
Dermatitis, Allergic Contact , Dermatitis, Photoallergic , Ketoprofen , Anti-Inflammatory Agents, Non-Steroidal , Benzophenones/adverse effects , Dermatitis, Allergic Contact/complications , Dermatitis, Allergic Contact/etiology , Dermatitis, Photoallergic/diagnosis , Dermatitis, Photoallergic/etiology , Gas Chromatography-Mass Spectrometry , Humans , Ketoprofen/adverse effects , Ketoprofen/chemistry , Patch TestsABSTRACT
BACKGROUND: UV filters are emerging contaminants with endocrine disrupting effects, but little is known about their health effects, especially for children. OBJECTIVE: To assess the association between multiple organic UV filters exposure and adiposity measures and by gender in peripubertal children. METHODS: This prospective follow-up study included 327 children aged 7-15 years old. Urinary organic UV filters including benzophenone derivatives (BP-2, BP-3), octyl dimethyl para-aminobenzoic acid (OD-PABA), ethylhexyl methoxycinnamate (EHMC) and its metabolite (4-MCA and 4'-MAP) were quantified. Six adiposity biometrics including height, weight, waist and hip circumferences, and triceps and subscapular skinfold thickness were measured with 1.5-year duration. The Bayesian kernel machine regression method was used to estimate the associations of UV filters mixture with adiposity measurements, and longitudinal analyses were then considered to further evaluate the associations between individual UV filters and trajectories of growth development using linear mixed models or generalized linear mixed models. RESULTS: Exposure to mixture of UV filters was negatively associated with most adiposity measurements, with a reduction of 1.399 kg/m2 (95% CI: -2.246 to -0.551 kg/m2) in BMI, 0.674 (95% CI: -1.045 to -0.304) in BMI z-score, 0.033 BF% (95% CI: -0.053 to -0.013), and 2.301 mm (95% CI: -3.823 to -0.78) in subscapular skinfold thickness at baseline, comparing the 75th percentile to the 25th level of UV filters mixture exposure. Consistent associations were found at follow-up. Both baseline and follow-up results suggested that EHMC was identified as the most important contributor to lower adiposity measurements, which was also confirmed by linear mixed models in longitudinal analyses. No significant effects were found in girls. CONCLUSION: This study found that childhood organic UV filters exposure was negatively associated with adiposity measures in peripubertal boys, but not girls.
Subject(s)
Adiposity , Benzophenones/adverse effects , Cinnamates/adverse effects , Pediatric Obesity/epidemiology , Sunscreening Agents/adverse effects , para-Aminobenzoates/adverse effects , Adolescent , Bayes Theorem , Body Mass Index , Child , China/epidemiology , Female , Follow-Up Studies , Humans , Male , Prospective Studies , Ultraviolet RaysABSTRACT
Benzophenone-3 (BP-3) is one of the most widely used chemical sunscreens. The results of many in vitro and in vivo tests confirm its high percutaneous penetration and systemic absorption, which question the safety of its wide use. The aim of our research was to assess the effect of this compound on components of the skin extracellular matrix, and to investigate whether rosmarinic acid (RA) could reduce BP-3-induced changes in human skin fibroblasts. BP-3 used at concentrations of 0.1-100 µM caused a number of unfavorable changes in the level of type I collagen, decorin, sulfated glycosaminoglycans, hyaluronic acid, elastin, and expression or activity of matrix metalloproteinases (MMP-1, MMP-2), elastase and hyaluronidase. Moreover, the intracellular retention of collagen was accompanied by changes in the expression of proteins modifying and controlling the synthesis and secretion of this protein. Most importantly, RA at a concentration of 100 µM significantly reduced or completely abolished the adverse effects of BP-3. Based on these findings, it can be concluded that this polyphenol may provide effective protection against BP-3-induced disturbances in skin cells, which may have important clinical implications.
Subject(s)
Benzophenones/adverse effects , Cinnamates/pharmacology , Depsides/pharmacology , Fibroblasts/metabolism , Benzophenones/metabolism , Cell Line , Cells, Cultured , Cinnamates/metabolism , Collagen/drug effects , Collagen/metabolism , Decorin/metabolism , Depsides/metabolism , Elastin/metabolism , Extracellular Matrix/drug effects , Extracellular Matrix/metabolism , Fibroblasts/drug effects , Glycosaminoglycans/metabolism , Humans , Hyaluronoglucosaminidase/metabolism , Matrix Metalloproteinases/metabolism , Skin/drug effects , Skin/metabolism , Rosmarinic AcidABSTRACT
Methylene blue (MB) is a century-old medicine, a laboratory dye, and recently shown as a premier antioxidant that combats ROS-induced cellular aging in human skins. Given MB's molecular structure and light absorption properties, we hypothesize that MB has the potential to be considered as a sunscreen active for UV radiation protection. In this study, we tested the effects of MB on UVB ray-induced DNA double-strand breaks in primary human keratinocytes. We found that MB treatment reduced DNA damages caused by UVB irradiation and subsequent cell death. Next, we compared MB with Oxybenzone, which is the most commonly used chemical active ingredient in sunscreens but recently proven to be hazardous to aquatic ecosystems, in particular to coral reefs. At the same concentrations, MB showed more effective UVB absorption ability than Oxybenzone and significantly outperformed Oxybenzone in the prevention of UVB-induced DNA damage and the clearance of UVA-induced cellular ROS. Furthermore, unlike Oxybenzone, MB-containing seawater did not affect the growth of the coral species Xenia umbellata. Altogether, our study suggests that MB has the potential to be a coral reef-friendly sunscreen active ingredient that can provide broad-spectrum protection against UVA and UVB.
Subject(s)
Aging/drug effects , Anthozoa/drug effects , Methylene Blue/pharmacology , Skin/drug effects , Aging/pathology , Aging/radiation effects , Animals , Antioxidants/pharmacology , Benzophenones/adverse effects , Coral Reefs , DNA Breaks, Double-Stranded/drug effects , DNA Breaks, Double-Stranded/radiation effects , DNA Damage/drug effects , DNA Damage/radiation effects , Ecosystem , Humans , Keratinocytes/drug effects , Keratinocytes/radiation effects , Light/adverse effects , Methylene Blue/chemistry , Radiation Protection , Skin/radiation effects , Sunscreening Agents/adverse effects , Ultraviolet Rays/adverse effectsABSTRACT
Introduction The combination of an anti-angiogenic agent with cytotoxic chemotherapy is a standard treatment strategy for metastatic colorectal cancer. CKD-516 is an oral vascular disrupting agent that was preliminarily shown to be safe and efficacious as a monotherapy in refractory solid cancers. We evaluated the recommended phase 2 dose, safety, and preliminary efficacy of CKD-516 in combination with irinotecan in treatment-refractory metastatic colorectal cancer. Methods This phase 1 dose-escalation and dose-expansion study included patients with treatment-refractory metastatic colorectal cancer. CKD-516 tablets were administered for five consecutive days followed by two days off in combination with intravenous irinotecan (120 mg/m2) administered on day one of each treatment cycle every two weeks. A traditional 3 + 3 dose-escalation design was used. Results In total, 16 and 23 patients were enrolled in the dose-escalation and dose-expansion cohorts, respectively. The most common adverse events included diarrhea (79%), nausea (74%), vomiting (67%), and neutropenia (62%). No dose-limiting toxicity occurred, and the recommended phase 2 dose was determined at CKD-516/irinotecan doses of 11/120 mg/m2. No cases of cardiac ischemia, cardiac dysfunction, or thromboembolism were reported. Among the 34 patients with available tumor response assessments, one patient achieved partial response (3%) and 26 patients achieved stable disease (76%). The median progression-free survival and overall survival were 4.1 and 11.6 months, respectively. Conclusion This phase 1 study showed that the combination of oral CKD-516 and irinotecan is safe and tolerable in metastatic, treatment-refractory colorectal patients and showed favorable efficacy outcomes. Further studies to confirm these preliminary findings are warranted. Trial registration number NCT03076957 (Registered at March 10, 2017).
Subject(s)
Antineoplastic Agents/therapeutic use , Benzophenones/therapeutic use , Colorectal Neoplasms/drug therapy , Valine/analogs & derivatives , Adult , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Antineoplastic Agents/pharmacokinetics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Area Under Curve , Benzophenones/administration & dosage , Benzophenones/adverse effects , Benzophenones/pharmacokinetics , Colorectal Neoplasms/pathology , Dose-Response Relationship, Drug , Female , Half-Life , Humans , Irinotecan/therapeutic use , Kaplan-Meier Estimate , Male , Maximum Tolerated Dose , Metabolic Clearance Rate , Middle Aged , Neoplasm Metastasis , Progression-Free Survival , Valine/administration & dosage , Valine/adverse effects , Valine/pharmacokinetics , Valine/therapeutic useABSTRACT
Radiolucent carbon-fiber-reinforced (CFR) polyethyl-ether-ether-ketone (PEEK) has been established in spinal instrumentation for oncological reasons. Laboratory data reported comparable bacterial adhesion as titanium. Thus, using of CFR-PEEK spinal instrumentation for spondylodiscitis bases on artifact-free imaging to evaluate therapeutic success. Studies comparing the rate of pedicle screw loosening and relapse of spondylodiscitis following titanium versus CFR-PEEK instrumentation do not exist so far. This study evaluates the rate of pedicle screw loosening and recurrence of spondylodiscitis after CFR-PEEK instrumentation for spondylodiscitis compared to titanium. We conducted a prospective single center study between June 2018 and March 2019 on consecutive 23 patients with thoracolumbar spondylodiscitis. Imaging data was evaluated for screw loosening at a minimum of three months after surgery. A matched-pair analysis was performed using spondylodiscitis cases between 2014 and 2016 using titanium instrumentation for equal localization, surgery, and microorganism class. Among 17 cases with follow-up imaging, six cases (35%) showed screw loosening while only 14% (two patients) with titanium instrumentation were loosened (p = 0.004). In both groups the most frequent bacterium was Staphylococcus aureus, followed by Staphylococcus epidermidis. From the S. aureus cases, one infection in both groups was caused by methicillin resistant species (MRSA). No difference was found in the rate of 360° fusion in either group due to matching criteria. As opposed to other indications CFR-PEEK screws show more loosening than titanium in this series with two potentially underlying reasons: a probably stronger bacterial adhesion on CFR-PEEK in vivo as shown by a statistical trend in vitro and instrumentation of spondylytic vertebrae. Until these factors are validated, we advise caution when implanting CFR-PEEK screws in infectious cases.
Subject(s)
Benzophenones/therapeutic use , Biocompatible Materials/therapeutic use , Carbon Fiber , Discitis/therapy , Polymers/therapeutic use , Adult , Aged , Aged, 80 and over , Benzophenones/adverse effects , Biocompatible Materials/adverse effects , Discitis/diagnosis , Discitis/etiology , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Polymers/adverse effects , Radiography , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
BACKGROUND: Little is known about the common photoallergens in New Zealand, where ultraviolet exposure is particularly high. Availability of photopatch testing is limited because of it being performed in very few tertiary referral and contact dermatitis clinics. OBJECTIVE: To review the photopatch testing experience in New Zealand. METHOD: A retrospective review of all patients who underwent photopatch testing at a tertiary referral center in Auckland from 2008 to 2019 was performed. RESULTS: Seventy patients had photopatch testing over the 12-year period. Of the 58 patients tested using the photoallergen series, 6 (10%) patients had a positive photopatch test reaction, of which 4 were to promethazine and 2 were to benzophenone-3. The most common postpatch diagnosis was endogenous dermatitis (54%), followed by allergic contact dermatitis (21%), photoallergic contact dermatitis (9%), and chronic actinic dermatitis (4%). CONCLUSIONS: Both patch and photopatch testing are important investigations in patients with suspected photoallergic contact dermatitis. Promethazine and benzophenone-3 were the most frequent and only photoallergens in our population. Promethazine sensitization was via oral exposure, supporting a mechanism of systematized photoallergy to promethazine.
Subject(s)
Dermatitis, Allergic Contact/diagnosis , Dermatitis, Photoallergic/diagnosis , Patch Tests , Photosensitivity Disorders/diagnosis , Ultraviolet Rays , Adult , Aged , Benzophenones/adverse effects , Cohort Studies , Dermatitis/diagnosis , Dermatitis, Allergic Contact/etiology , Dermatitis, Photoallergic/etiology , Female , Humans , Male , Middle Aged , New Zealand , Photosensitivity Disorders/chemically induced , Promethazine/adverse effects , Retrospective Studies , Tertiary Care CentersABSTRACT
Ex vivo mammary explant systems are an excellent model to study interactions between epithelium and stromal cell types because they contain physiologically relevant heterotypic interactions in the background of genetically diverse patients. The intact human mammary tissue, termed patient-derived explant (PDE), can be used to investigate cellular responses to a wide variety of external stimuli in situ. For this study, we examined the impact of cytokines or environmental chemicals on macrophage phenotypes. We demonstrate that we can polarize macrophages within human breast tissue PDEs toward M1 or M2 through the addition of interferon-γ (IFNγ) + lipopolysaccharide (LPS) or interleukin (IL)-4 + IL-13, respectively. Elevated expression levels of M(IFNγ + LPS) markers (HLADRA and CXCL10) or M(IL-4 + IL-13) markers (CD209 and CCL18) were observed in cytokine-treated tissues. We also examined the impact of the endocrine-disrupting chemical, benzophenone-3, on PDEs and measured significant, yet varying effects on macrophage polarization. Furthermore, a subset of the PDEs respond to IL-4 + IL-13 through downregulation of E-cadherin and upregulation of vimentin which is reminiscent of epithelial-to-mesenchymal transition (EMT) changes. Finally, we were able to show immortalized nonmalignant breast epithelial cells can exhibit EMT characteristics when exposed to growth factors secreted by M(IL-4 + IL-13) macrophages. Taken together, the PDE model system is an outstanding preclinical model to study early tissue-resident immune responses and effects on epithelial and stromal responses to stimuli found both endogenously in the breast and exogenously as a result of exposures.
Subject(s)
Breast/immunology , Environmental Exposure , Macrophage Activation , Benzophenones/adverse effects , Breast/drug effects , Cell Polarity , Endocrine Disruptors/adverse effects , Female , Humans , Macrophages/cytology , Tissue Culture TechniquesABSTRACT
We report a phase I pharmacological study of an oral formulation of CKD-516, a vascular-disrupting agent, in patients with refractory solid tumors. Twenty-seven patients (16 in the dose-escalation cohort and 11 in the expansion cohort) received a single daily dose (5-25 mg) of CKD-516 five days per week. Nausea (67%) and diarrhea (63%) were the most common treatment-related adverse events. The recommended phase II dose of oral CKD-516 was 20 mg/d (15 mg/d with a body surface area (BSA) <1.65 m2 ). Notably, S-516 half-lives in patients receiving 15-20 mg CKD-516/d significantly differed between patients with and without splenomegaly that is suggestive of portal hypertension associated with liver cirrhosis (6.1 vs 4.6 hours, respectively). Of 11 patients without splenomegaly who completed at least one cycle of a daily CKD-516 dose of either 15 or 20 mg, only one patient (9.1%) suffered from any dose-limiting toxicity. We conclude that a daily oral dose of 15 or 20 mg CKD-516 five days per week could be tolerable in patients without liver cirrhosis.
Subject(s)
Antineoplastic Agents/pharmacokinetics , Benzophenones/pharmacokinetics , Neoplasms/metabolism , Valine/analogs & derivatives , Administration, Oral , Adult , Aged , Antineoplastic Agents/adverse effects , Antineoplastic Agents/blood , Benzophenones/adverse effects , Benzophenones/blood , Female , Humans , Male , Middle Aged , Neoplasms/blood , Neoplasms/drug therapy , Treatment Outcome , Valine/adverse effects , Valine/blood , Valine/pharmacokinetics , Young AdultSubject(s)
Benzophenones/adverse effects , Benzophenones/immunology , Dermatitis, Allergic Contact/etiology , Dermatitis, Photoallergic/etiology , Eye Protective Devices/adverse effects , Aged , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Photoallergic/diagnosis , Humans , Male , Patch Tests/methods , Risk Assessment , Sensitivity and Specificity , SwimmingABSTRACT
As skin cancer prevalence continues to rise, the importance of sun protection, including sunscreen use, has become accepted in the public. Sunscreens are divided into two main categories based on the type of their active ingredient, organic and inorganic ultraviolet (UV) filters. It has been shown that inorganic filters are more effective at blocking forms of UV light, both UVA and UVB, as compared with organic filters because organic sunscreens absorb and convert radiation whereas inorganic sunscreens reflect radiation. The use of the two most common organic filters, oxybenzone and octinoxate, has recently been restricted in Hawaii due to their harmful effect on the coral reefs. Here, we discuss recent studies about these specific filters related to the adverse health risks they pose for humans and other organisms, as well as environmental repercussions.
Subject(s)
Benzophenones/adverse effects , Cinnamates/adverse effects , Benzophenones/therapeutic use , Cinnamates/therapeutic use , Environment , Humans , Hypothalamic Hormones/metabolism , Skin Neoplasms/prevention & control , Sunscreening Agents/adverse effects , Sunscreening Agents/therapeutic useABSTRACT
Sunscreen-containing skincare products protect the skin from damage caused by sun exposure. However, many of them contain oxybenzone and/or octinoxate, which have been reported to be toxic to juvenile coral and to cause coral bleaching. Thus, there is a growing need for new sunscreen compounds that are less harmful to the environment. Here, we report an engineered biosynthetic pathway employing genes from a vertebrate and two Gram-(+) bacteria that forms novel sunscreen compounds with hybrid structures of gadusol and mycosporine-like amino acids, both of which are found in marine environments. These compounds, named gadusporines, have unique UV absorbance at 340 nm, expanding the range of mycosporine- and gadusol-based sunscreen products. The synthesis of gadusporines in Streptomyces coelicolor establishes a platform for the design and production of novel sunscreens.
Subject(s)
Metabolic Engineering/methods , Rhodococcus/genetics , Streptomyces coelicolor/metabolism , Streptomyces/genetics , Sunscreening Agents/chemical synthesis , Zebrafish/genetics , Amino Acids/chemistry , Animals , Anthozoa/drug effects , Benzophenones/adverse effects , Benzophenones/pharmacology , Cinnamates/adverse effects , Cinnamates/pharmacology , Cyclohexanols/chemistry , Plasmids/genetics , Skin Cream/chemistry , Ultraviolet RaysABSTRACT
Introduction: Bromfenac is a topical ophthalmic non-steroidal anti-inflammatory drug (NSAID) used to reduce pain and treat post-operative inflammation after cataract surgery. Bromfenac 0.075% in the DuraSite™ vehicle is a newly-approved formulation which has been shown to be efficacious and safe for use in cataract surgery to reduce pain and treat inflammation. It has been shown to have a slightly better posterior segment ocular bioavailability compared to similar topical ophthalmic NSAIDs. However, there is a paucity of studies investigating its role in the prevention and treatment of post-operative pseudophakic cystoid macular edema. Areas covered: In this review, the authors provide an overview of similar products available, describe the novelty of bromfenac 0.075% in the DuraSite vehicle, and discuss the relevant clinical studies to determine if the formulation is safe and efficacious. Expert opinion: Bromfenac 0.075% in the DuraSite vehicle is a new topical ophthalmic medication which has been approved by the FDA for the prevention of pain and treatment of post-operative inflammation. It provides cataract surgeons with an additional medication for cataract surgery. However, no robust studies have been performed showing the effect that it has on the reduction or prevention of post-operative pseudophakic cystoid macular edema.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Benzophenones/therapeutic use , Bromobenzenes/therapeutic use , Cataract/pathology , Inflammation/drug therapy , Pain, Postoperative/drug therapy , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Benzophenones/adverse effects , Benzophenones/chemistry , Bromobenzenes/adverse effects , Bromobenzenes/chemistry , Cataract Extraction/adverse effects , Clinical Trials as Topic , Drug Compounding , Humans , Pain, Postoperative/etiology , Treatment OutcomeABSTRACT
Benzophenone-3 is used in a variety of cosmetic products as a sunscreen, and has shown weak estrogenic and antiandrogenic activity in animal and in vitro studies. Few studies have evaluated whether benzophenone-3 is associated with reproductive outcomes among women. We studied 304 women undergoing infertility treatment (2007-2017) in the prospective Environment and Reproductive Health cohort study and who underwent 449 treatment cycles (nâ¯=â¯788 urines). Generalized linear mixed models were used with random intercepts to account for multiple cycles, and adjusting for confounders including physical activity. Analyses were also stratified by self-reported moderate/heavy outdoor work. The cycle-specific median (IQR) urinary benzophenone-3 concentration was 147 (58, 462) µg/L, and 98% samples had detectable concentrations. Self-reported sunscreen use, physical activity, and time spent on moderate/heavy outdoor work were positively associated with urinary benzophenone-3. Adjusted probabilities of implantation, clinical pregnancy and live birth were higher in increasing quartiles of benzophenone-3, but these associations were restricted to women who reported spending time outdoors performing moderate/heavy work. Specifically, among these women, those in the highest quartile of benzophenone-3 concentrations had 51% higher implantation (p,trendâ¯=â¯0.02), 68% higher clinical pregnancy (p,trendâ¯=â¯0.01) and 75% higher live birth (p,trendâ¯=â¯0.02) adjusted probabilities than women in the lowest quartile. Benzophenone-3 was unrelated to these outcomes among women who did not report doing moderate/heavy work outdoors. These results confirm that sunscreen use is a source of benzophenone-3 exposure, and show positive associations between benzophenone-3 and pregnancy outcomes, especially among women who reported engaging in outdoor work. Since these associations may be subject to important residual confounding by lifestyle factors, further research is needed to confirm these novel results in other populations, and to investigate whether other factors may be affecting the relation of benzophenone-3 with fertility and other health outcomes.